Kentucky lawmakers are considering an expansion of the state's Right to Try Act, which would broaden access to experimental treatments that have not yet received approval from the U.S. Food and Drug Administration, according to testimony heard by state legislators.

The Right to Try Act currently permits patients diagnosed with rare and terminal diseases to seek access to investigational therapies outside the standard FDA approval process. Advocates of the expansion argue that current limitations prevent some patients from accessing potentially life-saving treatments during critical stages of their illnesses.

The proposed changes would allow a broader range of patients to petition for access to experimental drugs and medical devices, potentially including those with conditions that, while serious, may not meet the current definition of terminal illness. Supporters say the expansion would give desperate patients and their families additional options when conventional treatments have proven ineffective.

The testimony presented to lawmakers highlighted personal stories from patients and families affected by rare diseases who said they exhausted standard treatment options. Proponents argue that Right to Try expansions have proven successful in other states by allowing patients to benefit from promising experimental therapies while data is still being collected through formal clinical trials.

Kentucky is among numerous states examining ways to expand access to experimental treatments. The original federal Right to Try law, enacted in 2018, has served as a model for state-level expansions across the country, though the scope and specific provisions vary by jurisdiction.

The testimony suggests the proposed legislation has generated interest among lawmakers concerned with patient advocacy and medical innovation. The expansion would require careful consideration of patient safety protections and coordination with the FDA to ensure that expanded access does not compromise ongoing clinical research or put vulnerable patients at risk of unproven or ineffective therapies.